CRLF2 and acute lymphoblastic leukemia: The JAK1/2 inhibitor (i), ruxolitinib, is currently employed in a phase II clinical trial study of Ph-like ALL patients bearing CRLF2 alterations (ClinicalTrials.gov Identifier: NCT02723994).